Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of AMG 655 in Combination With Doxorubicin for the First-Line Treatment of Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma

NCT00626704 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00626704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00626704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of AMG 655 in Combination With Doxorubicin for the First-Line Treatment of Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma
Lead sponsor
Amgen
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2007
Completion date
March 31, 2011
Enrollment
134 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic, unresectable soft tissue sarcoma, sarcoma, soft tissue sarcoma